The current work was conducted to study the possible protective effect of melatonin, rosuvastatin and combination of them on nephrotoxicityinduced by amikacin in rats. Forty adult male albino rats were allocated into five groups (8 animalseach) and were treated daily for 2 weeks as follows: Group I: :( control group) treated with dimethylsulfoxide (DMSO) orally.GroupII: injected with daily dose of (120 mg/kg/IP) of amikacin ;Group III: injected with daily doseamikacin (120 mg/kg) with daily oral dose of melatonin (10 mg/kg); Group IV: injected with daily dose amikacin (120 mg/kg)with daily oral dose ofrosuvastatin (10 mg/kg);GroupV:animals were injected with daily dose amikacin (120 mg/kg) simultaneously treated with a combination of melatonin and rosuvastatin with the previously mentioned doses respectively. After 2 weeksblood samples were obtained for biochemical analyses. Then, rats were sacrificed and the kidneyswere collected for tissue homogenization and histopathological study. Results: amikacin administration induced significant increase in kidney weight, serumurea and creatinine, tumor necrosis factor (TNF-α), tissue malondialdehyde (MDA) levels and reduction in superoxide dismutase(SOD) activity. Simultaneous administration of melatonin and rosuvastatin treatment with amikacin significantly lowered the elevated serum urea and creatinine concentration, kidney weight, serum TNF-α and renal MDA andsignificantly enhance renal SOD activity with improvement of the kidney histological findings in comparison with group II. Conclusion: it could be concluded that combination of melatonin and rosuvastatin may be useful for reducing the nephrotoxic effects of amikacin.
Introduction
Aminoglycosides are potent bactericidal antibiotics; they are act particularly against aerobic, gram-negative microorganisms (1) . Amikacin is one of the most important aminoglycoside antibiotics, mostly used for treatment of severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as Acinetobacter, Enterobacter and Pseudomonas aeruginosa. (2) Amikacin has high anti-bacterial efficacy, rapid onset of action, synergy with other ß-lactam antibiotics, low resistance and low cost despite all their beneficial effects, their clinical uses is restricted because of nephrotoxicity and ototoxicity (3) . Aminoglycosides nephrotoxicity have been documented in numerous experimental studies (4) (5) . One mechanism of this toxicity is believed to be involved the generation of reactive oxygen radical species that are play a key role in a pathogenesis of aminoglycosides nephrotoxicity and it also has been shown that toxicity might be prevented with several antioxidants (6) (7) .Additionally, it has been demonstrated that aminoglycosides form a complex with mitochondrial Fe+² to catalyze the formation of free radicals (8) .
Melatonin (N-acetyl-5-methoxytryptamine) is a secretory product of pineal gland, might have a protective effect against free oxygen radicals by acting as a direct radical scavenger and indirect by up regulating the expression of several intracellular antioxidative enzymes such as superoxide dismutase(SOD), catalase (CAT), glutathione peroxidase (GPX) and glutathione reductase (GRd)as well as melatonin stimulatethe synthesis of important endogenous antioxidant such as glutathione GSH (9) .
It has been shown that melatonin attenuate the nephrotoxicity induced by a wide range of drugs that may cause oxidative stress in the cells of kidney including vancomycin, amikacin, and cisplatin (10) (11) (12) . Rosuvastatin belong to statins group of cholesterol-lowering agents that effectively decrease serum cholesterol levels by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG/CoA) reductase, thus reducing the production of mevalonate and cholesterol biosynthesis, therefore it is effective in prevention the primary and secondary cardiovascular diseases. Rosuvastatin has anti-inflammatory, immunomodulatory, antioxidant activities (13) (14) (15) . Rosuvastatin like other statins has been reported to attenuate inflammation through inhibition of inflammatory cytokines as well as recruitment of inflammatory cells (16, 17) . Numerous studies have been shown that the antioxidant potential of rosuvastatin is mediated through inhibition of NADPH oxidase (source of free radicals) and up regulating of cellular antioxidants including GSH and antioxidant enzymes such as SOD and CAT (18) (19) (20) (21) . Several studies have documented that rosuvastatin alleviated oxidative stress in amikacin induced renal injury (20) This study was designed to investigate the possible protective effects of melatonin, rosuvastatin and their combination against nephrotoxicity induced by amikacin.
Results

Effect of different treatment on kidney and body weight
Relative kidney weight highly significant increased (P˂0.001) in the amikacin treated group compared with control group which could be ameliorated significantly by melatonin and a combination of melatonin androsuvastatin treatment (P˂0.001). Whereas rosuvastatin treatment didn't show any effect on relative kidney weight in comparison with amikacin treated group (p> 0.05). Body weight was not affected in any animal groups as seen in table1. N=Number of animals; SEM = standard error of mean, a=Comparison with control group; b=Comparison with amikacin group, NS= Not statistically significant (p>0.05); *= statistically significant (p˂0.05); **= highly statistically significant (p˂ 0.001)
Effect of different treatments on serum creatinine levels
The mean of serum creatinine level of the control group (±SEM) was (0.617 ± 0.03) (mg/dl). It was significant elevated in amikacin group (P˂0.05)in which the mean of serumcreatinine level reached (1.261 ± 0.10) (mg/dl).In the melatonin and rosuvastatingroups, the means were (0.720 ± 0.07and0.800 ± 0.04) (mg/dl) respectively, which are significantly reduced in comparison with amikacin group (P <0.05) , while the mean of serum creatinine level in a combination of melatonin and rosuvastatin groups was (0.636 ± 0.04) which are highly significantly reduced in comparison with amikacin group(P˂0.001) as shownin the table 2.
Effect of different treatments on serum urea levels
The mean of serum urea level of the control group (±SEM) was (42.06 ± 1.73) (mg/dl). It was highly significant elevated in amikacin group (P˂0.001) in which the mean of serum urea level reached (94.62 ± 3.34) (mg/dl).In the groups treated with melatonin and a combination of melatonin and rosuvastatin ,the means were (58.65 ± 7.45and 55.62 ± 3.79) (mg/dl) respectively, which are highly significantly reduced in comparison with amikacin group (P<0.001) while the mean of serum urea level in groups treated with rosuvastatin was (71.85 ± 5.54) which are significantly reduced in comparison with amikacin group(p<0.05)as shown in the table 2. N=Number of animals; SEM = standard error of mean, a=Comparison with control group; b=Comparison with amikacin group, NS= Not statistically significant (p>0.05); *= statistically significant (p˂0.05); **= highly statistically significant (p˂ 0.001)
Table .2. Effects of melatonin and rosuvastatin and combination of them on
Effect of different treatments on serum TNF-αlevels
The mean of serum TNF-α level of the control group (±SEM) was (62.87 ± 1.85) (pg/ml). It was highly significant elevated in amikacin group (P<0.001) in which the mean of serum TNF-α level reached (90.00 ± 1.80) (pg/ml).In the groups treated with melatonin and a combination of melatonin and rosuvastatin , the means were (69.00 ± 2.81 and64.50 ± 2.67) (pg/ml) respectively, which are highly significant reduced in comparison with amikacin group (p< 0.001) while the mean of serum TNF-α level in group treated with rosuvastatin was (73.50 ± 2.23)(pg/ml) which are significantlyreducedin comparison with amikacin group(p< 0.05) as shown in the table 3. N=Number of animals; SEM = standard error of mean, a=Comparison with control group; b=Comparison with amikacin group, NS= Not statistically significant (p>0.05); *= statistically significant (p˂0.05); **= highly statistically significant (p˂ 0.001)
Effect of different treatments on serum SOD levels
Effect of treatments on histopathological score
The effect of amikacin on the renal functions showed significant elevation (p<0.05) in the histopathological scores of renal tissue of rats treated with amikacin (3.75 ± 0.16) compared to the corresponding value in the control group (0.00 ± 0.00) of animals. In the groups treated with melatonin, rosuvastatin and a combination of melatonin and rosuvastatin the value of histopathological scores of renal tissue of rats were (2.12 ± 0.12, 2.87 ± 0.12 and 0.875 ± 0.12) respectively, which are significantly reduced in comparison with amikacin group (P <0.05) as shown in the table 4.Histopathological examination of renal sections in different groups showed in figures 1, 2, 3, 4 and 5. 
Discussion
Nephrotoxicity is a major clinical complication of aminoglycoside antibiotics. Amikacin is one of most important aminoglycosides which is widely used for treatment of severe gram-negative bacterial infections. In spite of its clinical usefulness, there are constraints in using this drug as it is cause nephrotoxicity and ototoxicity.(31)It was early believed that aminoglycosides nephrotoxicity result from its re-absorption and accumulation in the renal proximal tubular cells (32) .Additionally, it has been reported that the free radicals are responsible for tubuloglomerular degeneration of the kidney, which is the pathogenesis of the oxidative stress associated with aminoglycosides nephrotoxicity (33) . The results of our study demonstrate that the amikacin had induced nephrotoxicity by causing significant elevation in the kidney/body weight ratio comparing with the control group (tables1) and this is may be attributed to the fact of the injection of nephrotoxic drugs lead to increase in the kidney weight and this was caused by swelling of renal tissue and this results are compatible with a studies done by (34) (35) .
In the present study, amikacin had induced nephrotoxicity by significant elevation of serum creatinine and urea levels in comparison with the control group (tables2).The elevation in serum creatinine and urea levels may be attributed to generation of reactive oxygen species (ROS) that play central key role in the mechanisms that lead to decrease glomerular filtration rate and renal tubular necrosis, so this will lead to reduced creatinine and urea clearance that is associated with elevation of serum urea and creatinine and this results are agreement with studies done by (36) (37) (38) .
In the present study, amikacin had induced nephrotoxicity by causing significant elevation of serum TNF-α level in comparison with the control group (table3) and this is may be attributed to the formation of ROS which activates nuclear factor kappa B (NF-KB)that has a key role in the initiating of inflammatory events and inducing renal damage (36, 38) In the present study, amikacin had induced nephrotoxicity by causing significant reduction of serum SOD level in comparison with the control group (table3) and this is may be related to the ability of aminoglycosides to generate ROS and these radicals are inactivate the antioxidant enzymes and alter their levels within renal tissues. When ROS production exceeds normal level of antioxidant enzymes, these enzymes are insufficient to metabolize all these radicals.Our results are in agreement with study done by (37) . Amikacin had induced nephrotoxicity by causing highly significant elevation of tissue MDA level comparing with the control group (table 3) and this is may be attributed to the involvement of oxidative stress in the nephrotoxicity and free radical production through lipid peroxidation these results are compatible with other studies (38) (39) (40) (41) . In the current work amikacin nephrotoxicity caused severe histopathological changes with high scores, these changes involvetubular cell swelling, vacuolation, desquamation , vascular congestion and necrosis these changes involving about 75% of renal tubules in comparison with control group (table 4) . It was reported that amikacin induce renal tissue damage via excessive oxidative stress and inflammation (38, (42) (43) .
Effect of melatonin against amikacin induced nephrotoxicity
The results of our study showed that treatment with melatonin induced significant decrease in kidney weight, serum levels of creatinine, urea, TNF-α, tissue MDA and histopathological scores as well as elevation in serum levels of SOD as compared to amikacin group (tables 1, 2, 3and 4) Melatonin prevents nephrotoxicity directly by scavenging ROS and RNS including hydroxyl radical ( • OH), singlet oxygen ( 1 O 2 ), hydrogen peroxide (H 2 O 2 ), superoxide radical (Ō • 2 ), nitric oxide (NO) and perioxynitrate anion (ONOŌ) and reduce their generation by inhibiting the activity of nitric oxide synthase (iNOS) (44) .So melatonin exert its antioxidant effect either directly by scavenging free radicals or indirectly by increasing the activity of antioxidant enzymes; superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), glutathione reductase (GRd) and the expression of endogenous antioxidant defense (glutathione). These antioxidant enzymes has an important role in metabolism of free radicals to less reactive species and then decreases of highly toxic byproducts i.e., when SOD dismutases Ō • 2 to H 2 O 2 which in turn, decrease free radical mediated cellular damage ; CAT converts H 2 O 2 to oxygen and water , GPX oxidizes GSH to glutathione disulfide (GSSG) then GRd reduce GSSG to GSH (45-46)therefore, the antioxidant capability of melatonin involve reducing the ROS production which is in turn leading to attenuation renal tubular necrosis , G B PCT tissue swelling andimprovement in the renal function and GFR and correct kidney weight, serum creatinine and urea levels (47) (48) (49) . Melatonin lower serum TNF-α and tissue MDA levels due its direct and indirect antioxidant properties and its strong anti-inflammatory action and this result agreed with studies that done by (50) (51) . Melatonin elevate serum SOD level and this is may be attributed to its antioxidant action that stimulate antioxidant enzyme and reduce ROS formation leading to decrease any depressor effect of these radicals on gene expression of antioxidant enzymes (46) .The results of our studyshowed that melatonin is effective in decreasing histopathological changes such ascellular swelling, vacuolation of cytoplasm with absence of desquamation and necrosis these changes involving about25% of renal tubules were observed(table 4) and this result is agreed with the studies (52) (53) .
Effects of rosuvastatin against amikacin induced nephrotoxicity
In the present study,rosuvastatin treatment results in an improvement of serum levels of creatinine, urea, TNF-α, SOD and tissue MDA as compared to amikacin group (tables 2, 3)as well as,rosuvastatin reduces scores of the histopathological changes as compared with amikacin group (table4) whereas rosuvastatin treatment didn't show any effect on relative kidney weight in comparison with amikacin treated group(Tables 1). Rosuvastatin reduce serum level of urea and creatinine by improving endothelial function, increase the bioavailability NO synthetase lead to improve the GFR or may be secondary to decreased ROS formation (54) (55) .Rosuvastatin lower serum TNF-α level and this is probably due to a reduction in the activity of nuclear factor kappa B (NF-Kb) and elevation in protein kinas B (PKB) activity (56) (57) .
Rosuvastatin enhance serum SOD level and this is may be attributed to its ability for inhibition of NADPH oxidase, which occur in the formation of superoxide anion so by inhibiting this enzymes, rosuvastatin may reduce the amount of superoxide radical, therefore SOD may be insufficiently consumed, and consequently , lead to an elevation in its level. (58) Rosuvastatin lowers tissue MDA level due to its ability for down/regulation of circulating levels of NADPH oxidase, one of the most important cellular sources of superoxide anion production. Our results are in agreement with some studies published so far (59) (60) Histopathological results showed minimal changes in renal tissue, cellular swelling, vacuolation, desquamation, congestion and necrosis these changes involving about 50% of renal tubules, indicating the influence of rosuvastatin treatment against amikacin induced nephrotoxicity.
Effect of combination drugs against amikacin induced nephrotoxicity
In combination group, the important results from present study were the synergism between melatonin and rosuvastatin when given to animals. The combination group showed significantly more reduction in kidney weight, biochemical parameters (serum levels of creatinine, urea), inflammatory parameter (TNF-α), oxidative stress parameter (tissue MDA) and the scores of histopathological changes and elevation in the activity of antioxidant parameter (SOD) when compared with amikacin group (all tables 1, 2, 3, 4).Furthermore, the combination group showed better amelioration effect in all parameters of the present study than either melatonin or rosuvastatin groups when being given separately.The reasonable explanations for this synergistic effect could be due to the concomitant effort of the different mechanisms of action of both melatonin and rosuvastatin because of anti-oxidant (17-21), anti-inflammatory (61-62) effects of rosuvastatin plus potent antioxidant effect of melatonin (45) (46) .
Conclusion
From the result of presented study, it could be concluded that the treatment of rats with melatonin and rosuvastatin inhibit amikacininduced nephrotoxicity, and it seems that melatonin can induced this effect more than rosuvastatin. Combination of melatonin and rosuvastatin in amikacin treated rats resulted in a marked decline in kidney weight and serum urea, creatinine, TNF-α and renal MDA levels and also significant elevation in serum SOD activity. These results suggested that the protective effect of melatonin and rosuvastatin may be caused by their antioxidant and anti-inflammatory properties.
